Stock Report: Oncolytics Biotech Inc. (ONCY) Report Updated: Jun 17, 2013 | Print This Page
Report Features:
Stock Analysis
Rating: Monthly View
| A |  |
|
|
 |
|
|
 |
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B | ||||||||||||
| C | ||||||||||||
| D | ||||||||||||
| F | ||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Rating: Weekly View
| This Week: | D  no change |
|---|---|
| Last Week: | D no change |
| Two Weeks Ago: | D no change |
Company Profile
Oncolytics Biotech Inc., a biotechnology company, focuses on the development of oncolytic viruses as potential cancers therapeutics. The company develops REOLYSIN, a human cancer therapeutic. Its clinical program includes various human trials comprising a Phase III clinical trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.
Recent News: Oncolytics Biotech Inc.
ADVERTISEMENT
My Portfolios (View All)
Save your portfolio—or a few for that matter—and check up on your stocks 24/7! Log in here.
Louis Navellier's Portfolios
- Blue Chip GrowthTop blue chips
- Emerging GrowthTop small-caps
- Ultimate GrowthFastest-moving
- Platinum GrowthElite Model Portfolio
Most Popular Stocks
Daily Leader Boards
Louis' Weekly Ratings
ADVERTISEMENT